IPSS Risk Score Calculator (Primary Myelofibrosis)
Use this tool to estimate the International Prognostic Scoring System (IPSS) risk category at diagnosis. Enter the patient values below and click Calculate.
| IPSS Factor | Threshold | Points |
|---|---|---|
| Age | > 65 years | 1 |
| Hemoglobin | < 10 g/dL | 1 |
| Leukocytes | > 25 ×109/L | 1 |
| Peripheral blasts | ≥ 1% | 1 |
| Constitutional symptoms | Present | 1 |
Educational use only. This calculator supports — but does not replace — specialist hematology assessment.
What is the IPSS in myelofibrosis?
The International Prognostic Scoring System (IPSS) is a classic risk model used in primary myelofibrosis (PMF), typically at diagnosis. It helps estimate disease risk by assigning one point for each adverse feature. Total points are grouped into risk categories that historically correlate with survival outcomes.
How this IPSS myelofibrosis calculator works
This calculator checks five clinical variables. Each positive risk factor contributes one point:
- Age over 65 years
- Hemoglobin below 10 g/dL
- Leukocyte count above 25 ×109/L
- Peripheral blood blasts at or above 1%
- Constitutional symptoms present (for example fever, weight loss, night sweats)
The final score ranges from 0 to 5. Higher scores indicate higher risk.
Risk category mapping
| IPSS Score | Risk Group | Typical Historical Median Survival* |
|---|---|---|
| 0 | Low | ~135 months |
| 1 | Intermediate-1 | ~95 months |
| 2 | Intermediate-2 | ~48 months |
| 3–5 | High | ~27 months |
*Values are from historical IPSS cohorts and should not be treated as an individual prediction. Newer therapies and molecular profiling can significantly change outlook.
Clinical context: IPSS vs DIPSS and molecular scores
IPSS remains useful because it is simple and broadly known, but modern care often uses additional tools:
- DIPSS (Dynamic IPSS): can be applied during disease course, not only at diagnosis.
- DIPSS-Plus: adds karyotype, platelet count, and transfusion dependence.
- MIPSS70 / MIPSS70+: integrates molecular and cytogenetic data for refined risk assessment.
In real practice, treatment planning (observation, JAK inhibition, transplant consideration, trial enrollment) is based on the full clinical picture, not a single score alone.
How to use your result responsibly
1) Confirm units and timing
Make sure values are entered in the correct units and reflect the correct time point (initial diagnosis for classic IPSS).
2) Review with a hematology specialist
Risk models are decision aids. They are most useful when interpreted with marrow findings, cytogenetics, mutations, symptom burden, age, frailty, and treatment goals.
3) Reassess over time
Myelofibrosis can evolve. Updated blood counts, symptoms, and molecular information may change management strategy.
Frequently asked questions
Does a higher IPSS score mean immediate aggressive treatment?
Not always. It signals higher risk, but treatment decisions also depend on symptoms, comorbidities, transplant eligibility, patient preference, and current therapeutic options.
Can this calculator diagnose myelofibrosis?
No. Diagnosis requires clinical and pathology evaluation. This tool only stratifies risk once PMF has been diagnosed.
Is this tool valid for secondary myelofibrosis?
IPSS was built for primary myelofibrosis at diagnosis. Secondary/post-ET/post-PV disease often requires different frameworks.
Bottom line
A solid ipss myelofibrosis calculator should be fast, transparent, and clinically faithful. Use the score as a structured discussion point with your care team — not as a standalone medical directive.